ReviewStem cell research & therapy2020
What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?
Review in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 1 synthesis or guideline pooled it, 246 citations in OpenAlex.
- Evolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review.Human reproduction update · 2024Pooled it
- Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial.Signal transduction and targeted therapy · 2026Trial
- Exosomes derived from AHR-overexpressing human umbilical cord mesenchymal stem cells attenuate H/R injury via AHR/NLRP3 pathway.Cell cycle (Georgetown, Tex.) · 2026Article
- Ambient intelligence-based framework for quantitative evaluation of cell culture operations to support standardization and training.Regenerative therapy · 2026Article
- Cord-Derived Stem Cells for Pediatric Autism Spectrum Disorder: Biological Rationale and Source-Specific Trial Design.International journal of molecular sciences · 2026Review
- A Layered Framework for Biological Aesthetics: A Narrative Review of Regenerative Medicine in Cosmetic Science.Cureus · 2026Review
- Human Umbilical Cord Mesenchymal Stem Cells Alleviate LPS-Induced Acute Lung Injury in Mice: Association with TLR4/MyD88/NF-κB Pathway Suppression.Biomedicines · 2026Article
- Current and emerging therapies for knee osteoarthritis: From conventional approaches to machine learning and stem cell innovations.Regenerative therapy · 2026Review
- SPHERpower: MSC spheroid-based bioequivalent lead to the efficient restoration of the scarred vocal folds.Stem cell research & therapy · 2026Article
- HECTD4 in human umbilical cord mesenchymal stem cells-derived exosomes alleviates osteoclast differentiation in osteoporosis progression by suppressing RANK m6A modification via promoting METTL3 ubiquitination.Journal of molecular histology · 2026Article
- 3D spheroids of umbilical cord-derived MSCs protect retinal pigment epithelium against oxidative and inflammatory injury by activating autophagy.Stem cell research & therapy · 2026Article
- Application of exosomes derived from mesenchymal stem cells in osteoarthritis.Journal of orthopaedic surgery and research · 2026Review
- Mesenchymal stem cell-based therapeutic strategies for female infertility: current evidence and emerging targeting approaches.Biotechnology letters · 2026Review
- Human umbilical cord mesenchymal stem cells alleviate hypoxic-ischemia-induced white-matter injury in neonatal rats by regulating polarization of microglia.Scientific reports · 2026Article
- From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2026Review
- Reproductive and Developmental Toxicity of Human Umbilical Cord Blood Mononuclear Cells.Biomedicines · 2026Article
- Intravenous Human Umbilical Cord-Derived Mesenchymal Stromal Cells Promote Functional Recovery after Experimental Intracerebral Hemorrhage Via Local and Systemic Immunomodulation.Translational stroke research · 2026Article
- Combined adipose- and umbilical cord-derived extracellular vesicles modulate inflammatory and chondrogenic signaling to promote cartilage repair.BioImpacts : BI · 2026Article
- Identifying key bioprocess variables using explainable machine learning to enhance culture efficiency and viability of umbilical cord-derived mesenchymal stem cells.International journal of medical sciences · 2026Article
- Protective effect of a novel hydrogel loaded with CM-UCMSCs on vitrified-thawed ovaries during in vitro culture.Frontiers in bioengineering and biotechnology · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman umbilical cord mesenchymal stem cells (HUC-MSCs) present in the umbilical cord tissue are self-renewing and multipotent. They can renew themselves continuously and, under certain conditions, differentiate into one or more cell types constituting human tissues and organs. HUC-MSCs differentiate, among others, into osteoblasts, chondrocytes, and adipocytes and have the ability to secrete cytokines. The possibility of noninvasive harvesting and low immunogenicity of HUC-MSCs give them a unique advantage in clinical applications. In recent years, HUC-MSCs have been widely used in clinical practice, and some progress has been made in their use for therapeutic purposes. MAIN BODY: This article describes two aspects of the clinical therapeutic effects of HUC-MSCs. On the one hand, it explains the benefits and mechanisms of HUC-MSC treatment in various diseases. On the other hand, it summarizes the results of basic research on HUC-MSCs related to clinical applications. The first part of this review highlights several functions of HUC-MSCs that are critical for their therapeutic properties: differentiation into terminal cells, immune regulation, paracrine effects, anti-inflammatory effects, anti-fibrotic effects, and regulating non-coding RNA. These characteristics of HUC-MSCs are discussed in the context of diabetes and its complications, liver disease, systemic lupus erythematosus, arthritis, brain injury and cerebrovascular diseases, heart diseases, spinal cord injury, respiratory diseases, viral infections, and other diseases. The second part emphasizes the need to establish an HUC-MSC cell bank, discusses tumorigenicity of HUC-MSCs and the characteristics of different in vitro generations of these cells in the treatment of diseases, and provides technical and theoretical support for the clinical applications of HUC-MSCs.
conclusionHUC-MSCs can treat a variety of diseases clinically and have achieved good therapeutic effects, and the development of HUC-MSC assistive technology has laid the foundation for its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.